Seeking talented molecular biologists to work in an interdisciplinary team environment on understanding how gene regulation is altered in cancer. This position will involve developing, optimizing and validating genome editing technologies. These methods will include CRISPR-Cas9 technologies for geneome editing and genetic perturbation as well as lentivirus production and transduction for the generation of engineered mammalian cell lines. Candidates will be expected to drive technology development and optimization with minimal supervision and to be able to troubleshoot as needed.
- Design experimental approaches with an understanding of how gene regulation is disordered in cancer, how it can be targeted, and the consequences of target pertubation on cell state
- Develop, optimize and run experimental protocols for CRISPR/Cas9 mediated endogenous tagging and/or knockout genes
- Generate CRISPR/lentiviral constructs via molecular cloning techniques including standard restriction, Gateway and Gibson technologies
- Annotate and maintain collaborative protocol repositories for all lab members
- Clearly communicate (oral and written) experimental results and progress
- Work collaboratively with chemical and molecular biologists to engineer mammalian cell lines than can be used to study the mechanism of gene regulation in cancer
Required: Masters degree in a basic science or equivalent. A Bachelor's degree in a basic science and two years of directly related experience will also be considered.
Required: One year of related experience. Competency in one or more key areas including: molecular biology, cell line engineering and gene regulation.
- Candidates should be able to design experimental approaches with an understanding of how gene regulation is disordered in cancer, how it can be targeted, and the consequences of target perturbation on cell state.
- Expertise in molecular cloning, virus generation, CRISPR/CAS9 technologies and mammalian cell culture.
The Lin lab studies cancer through the lens of gene control — the way in which genes in the genome are selectively and programmatically turned on and off. Altered gene control is a hallmark of cancer and we apply computational, molecular, and chemical biology approaches to better understand this process and how it affects tumor cell growth. We believe that targeting the gene control machinery is a novel, potent and feasible way to block the final common pathway of oncogenic signaling across a range of cancers.
Dr. Lin is a Pew-Stewart Scholar for Cancer Research, an Assistant Professor in the Department of Molecular and Human Genetics, and the Co-director of the Therapeutic Innovation Center at Baylor College of Medicine. He is a leader in the study of the “MYC” oncogene, the most commonly amplified human oncogene, and helped uncover its role as a general amplifier of transcription. Through his work he has also helped describe super-enhancers, control regions of the genome that activate oncogenes and can be selectively targeted by small molecules targeting chromatin and transcriptional regulators. Prior to joining the Baylor College of Medicine, Dr. Lin trained at the Dana-Farber Cancer Institute and earned his Ph.D. in Computational and Systems Biology from the Massachusetts Institute of Technology.
This position provides the opportunity to work alongside experts in many disciplines on projects directly connected to clinical data and pre-clinical modeling. As such, communication skills and the ability to work well in a team setting will be highly emphasized. Candidates with strong molecular biology and experimental backgrounds who demonstrate a strong inquisitive drive are encouraged to apply.